

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2020

Commission File Number 001-37381

**MEDIGUS LTD.**

(Translation of registrant's name into English)

**Omer Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

---

#### **EXPLANATORY NOTE**

On May 15, 2020, the Company issued a press release titled: “Medigus Signed an Exclusive Agreement with Elbit Systems Land for the Distribution in Mexico of Pandemic Response Ventilators for COVID-19 Patients”. A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

---

## EXHIBIT INDEX

Exhibit	Description
99.1	<a href="#"><u>Press release titled: “Medigus Signed an Exclusive Agreement with Elbit Systems Land for the Distribution in Mexico of Pandemic Response Ventilators for COVID-19 Patients”.</u></a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**MEDIGUS LTD.**

Date: May 15, 2020

By: /s/ Tatiana Yosef

Tatiana Yosef  
Chief Financial Officer

---



## **Medigus Signed an Exclusive Agreement with Elbit Systems Ltd for the Distribution in Mexico of Pandemic Response Ventilators for COVID-19 Patients**

**OMER, Israel, May 15, 2020- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS)**, a technology company developing minimally invasive tools and an innovator in direct visualization technology, announced today the signing of an exclusive distribution agreement with Elbit Systems Ltd, a subsidiary of Elbit Systems Ltd (Nasdaq and TASE: ESLT) for a period of one year.

Elbit Systems manufactures LifeCan, an innovative pandemic response ventilator. As part of the agreement, Medigus will obtain exclusive rights from Elbit Systems, for marketing and sale of this product to customers in Mexico.

Medigus will be responsible for obtaining and maintaining licenses and approvals required by the Mexican regulations, including health administration authorities. In order to start the regulatory process, Medigus acquired two LifeCan systems that will assist the company in obtaining the required permits for the marketing and selling of the ventilators.

The Coronavirus pandemic has exposed an acute global shortage of ventilators, highlighting the need for large-scale accessibility and deployment of ventilation devices in times of crisis. Hospital ventilator machines are expensive and must be reserved for the most critically ill patients.

The LifeCan ventilator was developed and invented by LifeCan Medical Ltd to provide cost-effective, mechanical ventilation for a wide range of clinical settings, for immediate and widescale deployment. Highly portable, Life-Can provides a readily available ventilation solution capable of extended operation at a stable and accurate frequency and volume, according to pre-defined parameters. The device features preset rate/tidal volume, built-in air pressure sensors, failure indicator, and a backup battery.

LifeCan ventilator is a proprietary technology that was developed by LifeCan Medical Ltd and designed in cooperation with doctors, engineers, quality and regulation personnel, to meet the standards of performance and safety required for emergency ventilators. The device is designed for quick and easy operation, intuitive for use by medical personnel, and with minimum training required for non-professional healthcare providers.

### **About Medigus**

Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company's advanced technology, please visit [www.medigus.com](http://www.medigus.com).

---

## Cautionary Note Regarding Forward Looking Statements

*This press release may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions and expectations of the company's management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent Medigus' expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved, due to inter alia the spread of COVID-19 as well as the restriction deriving therefrom. Nothing in the description herein should be understood or construed as an announcement of payments made to the Company for nor the successful supply of the ordered products. Each purchase and sale of LifeCan ventilators will be subject to the agreement of terms between Medigus, Elbit Systems and prospective customers and there is no guarantee that Medigus will obtain any purchases orders pursuant to the Distribution Agreement with Elbit Systems. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the company's activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to be medical or other advice of any kind.*

## Contact (for media only)

Tatiana Yosef  
Chief Financial Officer  
+972-8-6466-880  
ir@medigus.com

---